Nrp‐1 is beneficial for TGF‐β1 to enhance the stability of regulatory CD4+CD25+ T cells and may represent a novel therapeutic target with the potential to improve the CD4+CD25+ Tregs‐related primary negative immunoregulation associated with the TGF‐β1/Smads signaling pathway, especially Smad3, in sepsis. The gene discussed is SMAD3; the disease is Sepsis.